Theravance Biopharma, Inc. — Form 8-K
Filed September 18, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 12/100
What the filing says
Form 8-K filed 2026-09-18 reports Item 5.07 (Submission of Matters to a Vote of Security Holders). The filing contains no substantive disclosure of what was voted on, dollar amounts, share counts, percentages, or specific outcomes. Only the item code and filing mechanics are present in the disclosed text.
Why this rating
Bare administrative 8-K with no disclosed substance. Shareholder vote details absent from provided text. Routine periodic disclosure.
Extracted items
See more from September 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.